Completed Studies
Study MPSVI CSP
Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)
-
Indication
Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)
-
Investigational Therapeutic
Naglazyme® (galsulfase)
-
Study Type
Phase 4
-
Goal
The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data; to characterize the clinical response to long-term Naglazyme® (galsulfase) treatment; to further characterize the long-term safety of Naglazyme® treatment.
-
Status
This study has been completed